D-Mannose for UTI Prevention

Current Evidence on D-Mannose

The European Association of Urology (EAU) guidelines and the WikiGuidelines consensus statement classify D-mannose as having insufficient quality of evidence to enable a clear recommendation for UTI prevention 3, 4, 5
Despite biological plausibility for effectiveness, current evidence is limited by small sample sizes, heterogeneous study designs, and inconsistent results 2, 6
Only a few studies, including 3 randomized controlled trials and 2 prospective cohort studies, have evaluated D-mannose alone for UTI prevention 2

The European Urology guidelines strongly recommend methenamine hippurate for use in women without urinary tract abnormalities, as it works by releasing formaldehyde in acidic urine, resulting in bacteriostasis, and has been shown to be non-inferior to antibiotics for UTI prevention in multiple studies 3, 2, 6
The European Urology guidelines strongly recommend vaginal estrogen therapy for postmenopausal women, as it helps reduce vaginal atrophy, restore vaginal microbiome, and reduce UTI frequency, with minimal systemic absorption and no concerning safety signals regarding stroke, venous thromboembolism, or cancer risks 3, 1, 6
The European Urology guidelines weakly recommend cranberry products, which contain proanthocyanidins (PACs) that may prevent bacterial adhesion to urothelium, although evidence is contradictory 3, 1, 7
The European Urology guidelines strongly recommend antimicrobial prophylaxis when non-antimicrobial interventions have failed, with options including continuous or post-coital antibiotic regimens, although concerns about antibiotic resistance and side effects exist 3, 1, 8

Patients should be informed about the limited and contradictory evidence regarding the effectiveness of D-mannose for UTI prevention 1
D-mannose should be considered as part of a stepped approach, after trying interventions with stronger evidence, and patients should be monitored for efficacy and any adverse effects 3, 1, 2